Allergy Therapeutics plc

LSE AGY.L

Allergy Therapeutics plc Free Cash Flow Yield on January 14, 2025: -10.25%

Allergy Therapeutics plc Free Cash Flow Yield is -10.25% on January 14, 2025, a 99.66% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Allergy Therapeutics plc 52-week high Free Cash Flow Yield is -10.11% on January 06, 2025, which is 1.42% above the current Free Cash Flow Yield.
  • Allergy Therapeutics plc 52-week low Free Cash Flow Yield is -2,999.84% on January 16, 2024, which is -29,163.86% below the current Free Cash Flow Yield.
  • Allergy Therapeutics plc average Free Cash Flow Yield for the last 52 weeks is -89.16%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
LSE: AGY.L

Allergy Therapeutics plc

CEO Mr. Manuel Llobet
IPO Date Oct. 11, 2004
Location United Kingdom
Headquarters Dominion Way
Employees 612
Sector Health Care
Industries
Description

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

StockViz Staff

January 15, 2025

Any question? Send us an email